Transcription factors are proteins that bind DNA regulatory sequences and control the expression of target genes. When mutated, amplified, or constitutively activated, transcription factors can drive cancer through dysregulated gene expression programmes affecting cell cycle entry, survival, metabolism, and immune evasion simultaneously. Unlike kinases with well-defined ATP-binding pockets, transcription factors typically lack drugable enzymatic cavities, making them historically resistant to direct pharmacological inhibition. MYC and STAT3 are the most clinically important oncogenic transcription factors, dysregulated in the majority of human cancers.
MYC heterodimerises with MAX via bHLH-LZ domains and binds E-box sequences genome-wide, driving a transcriptional programme including ribosome biogenesis, glycolysis, cell cycle entry, and immune evasion genes. STAT3 is phosphorylated at Tyr705 by JAK kinases, dimerises via reciprocal SH2-pTyr interaction, and binds GAS elements to transcribe anti-apoptotic (BCL2, MCL1), proliferative (cyclin D1), and immunosuppressive (IL-10, PD-L1) genes. Both transcription factors create broad oncogenic programmes that simultaneously promote growth, survival, and immune evasion.
MYC heterodimerises with MAX via bHLH-LZ domains and binds E-box sequences genome-wide, driving a transcriptional programme including ribosome biogenesis, glycolysis, cell cycle entry, and immune evasion genes. STAT3 is phosphorylated at Tyr705 by JAK kinases, dimerises via reciprocal SH2-pTyr interaction, and binds GAS elements to transcribe anti-apoptotic (BCL2, MCL1), proliferative (cyclin D1), and immunosuppressive (IL-10, PD-L1) genes. Both transcription factors create broad oncogenic programmes that simultaneously promote growth, survival, and immune evasion.
Mitogenic signalling (RAS/ERK, WNT/β-catenin) drives MYC mRNA and protein accumulation. ERK phosphorylates MYC at Ser62, stabilising the protein by preventing GSK3β-mediated Thr58 phosphorylation (which targets MYC for FBXW7 ubiquitination). MYC half-life extends from ~20 to 60+ minutes under sustained signalling.
MYC heterodimerises with MAX via bHLH-LZ domains, forming a high-affinity complex with sequence-specific DNA binding activity at E-box motifs (CACGTG). In MYC-amplified cells, MYC-MAX invades enhancers genome-wide in a near-indiscriminate fashion, amplifying expression of already-active genes rather than selectively activating silent targets.
MYC-MAX recruits TRRAP (scaffold for HAT complexes), P-TEFb (CDK9/cyclin T for RNA Pol II pause release), and BRD4 (acetyl-lysine reader for active enhancers). Together these complexes hyperactivate RNA Pol I, II, and III simultaneously — dramatically expanding ribosome biogenesis and translational capacity.
IL-6 receptor activation triggers JAK1/JAK2 trans-autophosphorylation. JAK kinases phosphorylate gp130-associated STAT3 at Tyr705. Phospho-Tyr705 forms an SH2-pTyr dimer interface with a second STAT3 monomer, creating the activated dimer that translocates to the nucleus.
Direct inhibition of MYC-MAX or STAT3 SH2 dimerisation is challenging. Indirect strategies include BET bromodomain inhibitors (JQ1, OTX015) that displace BRD4 from MYC super-enhancers, reducing MYC transcription; Aurora A inhibitors that destabilise MYC protein; and JAK inhibitors (ruxolitinib) that suppress upstream STAT3 phosphorylation.
MYC is dysregulated in ~70% of human cancers; MYCN amplification is a defining poor-prognosis feature in high-risk neuroblastoma. STAT3 constitutive activation occurs in ~70% of haematological malignancies, hepatocellular carcinoma, and many solid tumours. The transcription factor nature of these oncoproteins — simultaneously controlling hundreds of target genes — explains why their inhibition can be so effective: a single upstream hit suppresses an entire oncogenic programme.
Transcription factors are difficult to inhibit directly, so research often targets dependencies that sustain their expression or activity. BET-bromodomain, CDK7 and Aurora-A strategies have been studied in selected MYC-driven models and trials, while JAK inhibition can reduce upstream STAT signalling in defined diseases. None of these mechanisms makes MYC or STAT3 status a stand-alone treatment instruction; agent identity, target engagement, tumour lineage and current trial status must be verified.
Why is MYC so difficult to target directly?
MYC lacks a classic enzyme active site (ATP-binding pocket, substrate groove) that small molecules can occupy with selectivity. Its interactions with MAX and DNA occur over large protein-protein and protein-DNA interfaces without deep, druggable cavities. Additionally, MYC is intrinsically disordered (no stable three-dimensional structure) until it binds MAX, making structure-based drug design challenging. Indirect approaches targeting MYC transcription (BET inhibitors), translation, or protein stability are therefore more tractable.
How does STAT3 drive immune evasion in tumours?
Tumour STAT3 constitutive activation transcribes immunosuppressive factors: IL-10 and TGF-β suppressing cytotoxic T-cell and NK cell function; PD-L1 engaging PD-1 on T cells to induce anergy; VEGFA creating an immunosuppressive vasculature with low T-cell trafficking; and IDO1 depleting tryptophan needed for T-cell proliferation. STAT3 simultaneously protects tumour cells from killing and suppresses the immune system's ability to execute killing.
How MYC reshapes transcription, ribosome biogenesis, metabolism and cell-cycle control—and why MYC dependencies and therapeutic strategies vary by context.
How proto-oncogenes become oncogenes through point mutation, amplification, and translocation — and how modern targeted therapies exploit oncogene dependency.
How BCL2-family proteins control the mitochondrial apoptosis decision, how cancer cells exploit BCL2/MCL1 overexpression for survival, and how venetoclax exploits BCL2 dependency.
Understand sensitising EGFR mutations in NSCLC, how molecular testing is interpreted, and how T790M, C797S, MET amplification and other resistance mechanisms differ.
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
Cell Cycle Regulation Genes
Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regula…
EGFR–KRAS–BRAF–MEK–ERK Signalling Pathway in Cancer
The EGFR signalling pathway converts extracellular EGF binding into intracellular proliferative and survival signals via…
RAS/MAPK Signalling Pathway
The RAS/RAF/MEK/ERK (MAPK) cascade is one of the most ancient and conserved proliferative signalling pathways in eukaryo…
Tumor Angiogenesis
As solid tumours enlarge, diffusion limits create regions of hypoxia and nutrient stress. Many tumours respond by increa…
DNA Damage Response Genes
Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication e…